Hydroxychloroquine sulphate

This case report describes a 37-year-old female with systemic lupus erythematosus who developed multiple eruptive dermatofibromas; lesions spontaneously resolved and highlight the rare coexistence of these conditions.

This study documented the progression of exfoliative cutaneous lupus erythematosus in German shorthaired pointers and found generally poor responses to therapies, including immunomodulatory drugs and a TNF-α inhibitor.

This article discusses the efficacy and safety of mycophenolate mofetil and hydroxychloroquine for treating lichen planopilaris and reports no new clinical results.

In this case report, a 37-year-old man with discoid lupus erythematosus experienced around 80% hair regrowth after treatment with a combination of oral and topical therapies.

This article reviews various types of primary cicatricial alopecias and emphasizes the importance of accurate diagnosis to improve management strategies, particularly detailing remaining lymphocytic forms and expanding on neutrophilic and mixed types.

This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

This review discusses potential therapeutic options for frontal fibrosing alopecia by exploring distinct signaling pathways and cellular players, but reports no new clinical findings and emphasizes the need for further trials.

The EADV Task Force on Hair Diseases reviewed existing literature and clinical experience to propose diagnostic and therapeutic recommendations for managing folliculitis decalvans, highlighting oral antibiotics, glucocorticosteroids, isotretinoin, and various systemic and topical therapies as key options for managing inflammation and preventing further hair loss.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

This review highlights that drug repositioning offers a cost-effective alternative to traditional drug discovery, especially for treating orphan and resistant diseases like COVID-19, by repurposing existing drugs such as Hydroxychloroquine and Remdesivir.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

This review discusses evidence-based guidance for managing primary cicatricial alopecias but reports no new clinical results, highlighting significant gaps in knowledge and the need for more quality trials.

This review discusses the potential of herbal treatments like Saw palmetto, Green tea, and Rosemary as alternatives to conventional drugs for androgenetic alopecia, noting that these herbs may inhibit the 5-alpha-reductase enzyme and reduce hair loss with fewer side effects.

This report discusses two cases of sarcoidosis with cutaneous manifestations that posed a diagnostic challenge, without presenting new clinical results.

This review discusses madarosis, its diverse causes, and suggests follicular unit transplantation as a useful treatment for scarring types, but reports no new clinical results.

This research analyzed 72 primary scarring alopecia cases in a Barcelona hospital, finding that the majority involved women, with a lymphocytic infiltrate and subacute onset in many cases, leading to stable disease, while neutrophilic cases had more acute episodes.

This study found that finasteride- and minoxidil-loaded nanoparticles in a gel improved skin permeability and drug retention, suggesting a promising approach for topical alopecia treatment with reduced dosing frequency and side effects.

This review discusses the pathomechanism and pathology of alopecia areata, its classifications, and associated diseases, but reports no new clinical results, highlighting the importance for current and future treatment considerations.

Terbinafine can cause hair loss.